GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response

Cancer Letters

Volumn 309, Issue 1, 2011, Pages 37-45

  Chen, Baishen ^a,c   Rao, Xi ^d   House, Michael G ^a   Nephew, Kenneth P ^a,e   Cullen, Kevin J ^b   Guo, Zhongmin ^a,e  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SUN YAT SEN UNIVERSITY   (China)

^d INDIANA UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant enzymes; Chemotherapy response; DNA methylation; Head and neck cancer; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GPX3 GENE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE PEROXIDASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASMS; POLYMERASE CHAIN REACTION; PROGNOSIS; TREATMENT OUTCOME;

EID: 79959838676     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.013     Document Type: Article

References (51)

1. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
2. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
3. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148-1159.
4. Mulero-Navarro S., Esteller M. Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 2008, 68:1-11.
5. Baylin S.B. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2005, 2(Suppl. 1):S4-11.
6. Hagen T.M., Huang S., Curnutte J., Fowler P., Martinez V., Wehr C.M., Ames B.N., Chisari F.V. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 1994, 91:12808-12812.
7. Reddy M.B., Clark L. Iron, oxidative stress, and disease risk. Nutr. Rev. 2004, 62:120-124.
8. Waris G., Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J. Carcinog. 2006, 5:14.
9. Malins D.C. Free radicals and breast cancer. Environ. Health. Perspect. 1996, 104:1140.
10. Rodgman A., Smith C.J., Perfetti T.A. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Hum. Exp. Toxicol. 2000, 19:573-595.
11. Retel J., Hoebee B., Braun J.E., Lutgerink J.T., van den Akker E., Wanamarta A.H., Joenje H., Lafleur M.V. Mutational specificity of oxidative DNA damage. Mutat. Res. 1993, 299:165-182.
12. Behrend L., Henderson G., Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 2003, 31:1441-1444.
13. Wada T., Penninger J.M. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004, 23:2838-2849.
14. Valko M., Izakovic M., Mazur M., Rhodes C.J., Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 2004, 266:37-56.
15. Davis W., Ronai Z., Tew K.D. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J. Pharmacol. Exp. Ther. 2001, 296:1-6.
16. Takebe G., Yarimizu J., Saito Y., Hayashi T., Nakamura H., Yodoi J., Nagasawa S., Takahashi K. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J. Biol. Chem. 2002, 277:41254-41258.
17. Karihtala P., Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007, 115:81-103.
18. Peng D.F., Razvi M., Chen H., Washington K., Roessner A., Schneider-Stock R., El-Rifai W. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 2009, 58:5-15.
19. Lee O.J., Schneider-Stock R., McChesney P.A., Kuester D., Roessner A., Vieth M., Moskaluk C.A., El-Rifai W. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 2005, 7:854-861.
20. Yu Y.P., Yu G., Tseng G., Cieply K., Nelson J., Defrances M., Zarnegar R., Michalopoulos G., Luo J.H. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 2007, 67:8043-8050.
21. Lodygin D., Epanchintsev A., Menssen A., Diebold J., Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res. 2005, 65:4218-4227.
22. Cullen K.J., Newkirk K.A., Schumaker L.M., Aldosari N., Rone J.D., Haddad B.R. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res. 2003, 63:8097-8102.
23. Tokumaru Y., Yamashita K., Osada M., Nomoto S., Sun D.I., Xiao Y., Hoque M.O., Westra W.H., Califano J.A., Sidransky D. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004, 64:5982-5987.
24. Wu G., Guo Z., Chang X., Kim M.S., Nagpal J.K., Liu J., Maki J.M., Kivirikko K.I., Ethier S.P., Trink B., Sidransky D. LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res. 2007, 67:4123-4129.
25. Xing M., Usadel H., Cohen Y., Tokumaru Y., Guo Z., Westra W.B., Tong B.C., Tallini G., Udelsman R., Califano J.A., Ladenson P.W., Sidransky D. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 2003, 63:2316-2321.
26. Yang H., Kadia T., Xiao L., Bueso-Ramos C.E., Hoshino K., Thomas D.A., O'Brien S., Jabbour E., Pierce S., Rosner G.L., Kantarjian H.M., Garcia-Manero G. Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood 2009, 113:1892-1898.
27. Jee C.D., Kim M.A., Jung E.J., Kim J., Kim W.H. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 2009, 45:1282-1293.
28. Prado E., Wurtz T., Ferbus D., Shabana el H., Forest N., Berdal A. Sodium fluoride influences the expression of keratins in cultured keratinocytes. Cell Biol. Toxicol. 2011, 27:69-81.
29. Sieger S., Jiang S., Kleinschmidt J., Eskerski H., Schonsiegel F., Altmann A., Mier W., Haberkorn U. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Ther. 2004, 11:41-51.
30. Kim M.M., Glazer C.A., Mambo E., Chatterjee A., Zhao M., Sidransky D., Califano J.A. Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol. 2006, 42:201-207.
31. Jaiyesimi I.A., Buzdar A.U., Hortobagyi G. Inflammatory breast cancer: a review. J. Clin. Oncol. 1992, 10:1014-1024.
32. Malins D.C., Polissar N.L., Gunselman S.J. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl. Acad. Sci. USA 1996, 93:2557-2563.
33. Malins D.C., Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res. 1991, 51:5430-5432.
34. Chen X., Ding Y.W., Yang G., Bondoc F., Lee M.J., Yang C.S. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 2000, 21:257-263.
35. Brigelius-Flohe R., Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta 2009, 1790:1555-1568.
36. Fang J., Nakamura H., Iyer A.K. Tumor-targeted induction of oxystress for cancer therapy. J. Drug Target 2007, 15:475-486.
37. Conklin K.A. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr. Cancer 2000, 37:1-18.
38. Haffty B.G., Glazer P.M. Molecular markers in clinical radiation oncology. Oncogene 2003, 22:5915-5925.
39. Schumaker L., Nikitakis N., Goloubeva O., Tan M., Taylor R., Cullen K.J. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin. Cancer Res. 2008, 14:5877-5883.
40. Shiga H., Heath E.I., Rasmussen A.A., Trock B., Johnston P.G., Forastiere A.A., Langmacher M., Baylor A., Lee M., Cullen K.J. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin. Cancer Res. 1999, 5:4097-4104.
41. Cullen K.J., Schumaker L., Nikitakis N., Goloubeva O., Tan M., Sarlis N.J., Haddad R.I., Posner M.R. Beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. J. Clin. Oncol. 2009, 27:6222-6228.
42. Nichols A.C., Finkelstein D.M., Faquin W.C., Westra W.H., Mroz E.A., Kneuertz P., Begum S., Michaud W.A., Busse P.M., Clark J.R., Rocco J.W. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin. Cancer Res. 2010, 16:2138-2146.
43. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002, CA. Cancer J. Clin. 2002, 52:23-47.
44. Forastiere A.A. Overview of platinum chemotherapy in head and neck cancer. Semin. Oncol. 1994, 21:20-27.
45. Seve P., Dumontet C. Chemoresistance in non-small cell lung cancer. Curr. Med. Chem. Anticancer Agents 2005, 5:73-88.
46. Smith M.L., Fornace A.J. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol. 1995, 7:69-75.
47. Manic S., Gatti L., Carenini N., Fumagalli G., Zunino F., Perego P. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr. Cancer Drug Targets 2003, 3:21-29.
48. Brozovic A., Ambriovic-Ristov A., Osmak M. The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 2010, 40:347-359.
49. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell Biochem. 2008, 104:657-667.
50. Furuichi M., Yokozuka M., Takemori K., Yamanashi Y., Sakamoto A. The reciprocal relationship between heme oxygenase and nitric oxide synthase in the organs of lipopolysaccharide-treated rodents. Biomed. Res. 2009, 30:235-243.
51. Steinkamp-Fenske K., Bollinger L., Xu H., Yao Y., Horke S., Forstermann U., Li H. Reciprocal regulation of endothelial nitric-oxide synthase and NADPH oxidase by betulinic acid in human endothelial cells. J. Pharmacol. Exp. Ther. 2007, 322:836-842.